



EZZ

FY24 Results Presentation

Glenn Cross, Non-Executive Director and Chair
Tony Guarna, Chief Financial Officer

Disclaimer

This document has been prepared by EZZ Life Science Holdings Limited ACN 608 363 604 (Company). By accepting a copy of this document you warrant and undertake to the Company that you agree to be bound by the terms and conditions set out below.

This document is not a prospectus, product disclosure statement or other offer document under Australian law or under any other law and has not been filed, registered or approved by regulatory authorities in any jurisdiction. This document does not constitute an offer, invitation, solicitation or recommendation to acquire any shares in the Company. The information contained in this document is not intended to be relied upon as advice or a recommendation to investors and does not take into account the investment objectives, financial situation, taxation situation or needs of any particular investor. An investor must not act on the basis of any matter contained in this document but must make its own assessment of the Company and conduct its own investigations and analysis. Investors should assess their own individual financial circumstances and consider talking to a financial adviser, professional adviser or consultant before making any investment decision. The information contained in this document is supplied in summary form and does not contain all information necessary to make an investment decision.

Neither the Company nor any of its directors, officers, employees, contractors, agents or advisers (Limited Party) makes any representations or warranties, express or implied, as to or takes responsibility for, the accuracy, reliability, completeness or fairness of the information, opinions, forecasts, reports, estimates and conclusions contained in this document. No Limited Party represents or warrants that this document is complete or that it contains all information about the Company that a prospective investor may require in evaluating a possible investment in the Company. To the maximum extent permitted by law, each Limited Party expressly disclaims any and all liability, including, without limitation, any liability arising out of fault, negligence or omission on the part of any person, for any loss or damage arising from the use of, or reliance on, information contained in this document or otherwise arising in connection with it.

Certain statements in this document constitute forward looking statements and comments about future events, including with respect to the financial condition, results of operations and business of the Company and certain plans and objectives of the management of the Company. Such forward looking statements involve known and unknown risks, uncertainties, assumptions and other important factors, many of which are beyond the control of the Company and which may cause actual results, performance or achievements to differ materially from those expressed or implied by such statements. Forward looking statements are provided as a general guide only, and should not be relied on as an indication or guarantee of future performance. Given these uncertainties, you are cautioned to not place undue reliance on any forward looking statement. Past performance is not indicative of future performance and no guarantee of future returns is implied or given. Nothing contained in this document nor any information made available to you is, or shall be relied upon as, a promise, representation, warranty or guarantee as to the past, present or the future performance of the Company. No Limited Party or any other person makes any representation as to the accuracy or likelihood of the fulfilment of any forward-looking statements, or gives any assurance or guarantee that the occurrence of the events expressed or implied in any forward looking statements in this document will occur.

Contents

- FY24 Highlights
- FY24 Financial Performance
- Company Strategy
- Looking Forward
- Q&A



FY24 Highlights

EZZ



Strong Financial Performance

Strong revenue growth of 79% from \$37.1m in FY23 to \$66.4m in FY24

Gross margin stable above 75% for the period

Strong cash position of \$19.0m (no external debt)



New Distribution Channels and Geographical Markets

Strong growth on the Douyin and Tmall Global platforms continue

New presence on Kuaishou and Pinduoduo e-commerce channels in China

Building distribution network in new geographies including Vietnam



New Product Development

21 new products launched under the EZZ brand in FY24 and distributed several new products under the EÁORON brand

Consumer insights from e-commerce presence provide deep knowledge of consumer preferences

High safety standards with TGA product registrations and manufacturing under GMP principles

FY24 Financial Performance

FY24 Financial Overview



Revenue

\$66.4M

Up by 78.9% YoY

EBITDA

\$10.4M

Up by 103.80% YoY

Cash on Hand

\$19.0M

No external debt

Gross Margin

75%+

Steady for the period

NPAT

\$6.9M

Up by 91.8% YoY

Dividend


1.5 cents

1H FY24 Interim


Revenue

Record revenue growth due to successful market-driven R&D, dynamic channel prioritisation, and targeted B2C marketing

Revenue Drivers




Revenue by Segment



Margins

Attractive gross margin are well maintained and improving


Gross Margin




Profitability

Solid operating profit and strong growth momentum fuelled by successful investments in marketing

EBITDA (Excluding Other Income)



Operating Expense Breakdown



Working Capital

Well maintained working capital position to accelerate continuous growth

Working Capital Movements



Cash Flow

Cash flow from operating activities has more than doubled from a year ago


Cash Flow Movements




Revenue Mix

Increasingly diversified revenue streams across multiple distribution channels and geographic regions

Revenue by Channel



Revenue by Geography



Financial Position



¹ Excluding lease liabilities

Company Strategy

The EZZ Mission

To become a leading life science company in the Asia-Pacific, improving quality of life and human health by accelerating innovation to market.



Company Pillars

EZZ

Life Science



Product development pipeline to increasingly feature healthcare solutions based on scientific research.

- TGA product registration
- Manufactured under Australian Good Manufacturing Practice (GMP) principles

Technology



Online store and data backed analytical capabilities enable data driven decision making.

- Streamlined process with real-time data
- Personalised customer experience
- Pricing and promotion structures flexibility

Distribution



Focus on top-tier distributors in target markets with proven customer success.

- Cultural compatibility
- Engagement models diversification

Consumers



Connection to consumers through omnichannel strategies in targeted sectors and regions.

- Wholesalers
- Retailers
- E-commerce
- Social commerce and selling



Diverse Product Range

EZZ

EZZ

We formulate, produce, market and distribute health supplements under the brand of EZZ. Our deep understanding of our target consumers allows us to develop products that address their health and wellness needs.

Top 3 Products by Revenue in FY24



NMN
175,000 mcg



L-Lysine Growth
Capsule



Bone Growth
Chews

EÁORON

We are an exclusive distributor of skin care products under the EÁORON brand in Australia and New Zealand to pharmacies, supermarkets and specialist retailers.

Top 3 Products by Revenue in FY24



Hyaluronic Acid
Glutathione Essence
Face Mask



Hyaluronic Acid
Glutathione Essence



Niacinamide
Mask

Extensive Distribution Capabilities

Strong omnichannel marketing capabilities have delivered results

Chemists

600+



Specialist and Grocery Retailers

200+



E-commerce Platforms

750+



Looking Forward

- **US market entry:** EZZ has established a TikTok store and engaged relevant third-party partners to support the Company's US market entry. The Company expects to commence sales in Q2 FY25.
- **New products:** EZZ expects to launch 10 new products in 1H FY25 in addition to the four functional food products announced in Q1 FY25.
- **China growth:** EZZ expects recently announced strategic relationships to continue to drive strong growth in the Chinese market.
- **Acquisition opportunities:** EZZ management continues to actively look for synergistic ways to further enhance the scale of the business.



Q&A

EZZ Life Science Holdings Limited

ASX: EZZ



Contact

EZZ Life Science Holdings Limited
ABN 83 608 363 604

104 Derby Street,
Silverwater NSW 2128

T: 02 9160 2305
E: ir@ezzlifescience.com.au

www.ezzlifescience.com.au



EZZLifescience



linkedin.com/company/ezz-life-science-holdings



EZZAustralia



EZZ_Australia